Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Elotuzumab in Multiple Myeloma

Studied with lenalidomide and dexamethasone

Publish date:: August 25, 2015

Patients with relapsed or refractory multiple myeloma who received a combination of elotuzumab, lenalidomide, and dexamethasone had a significant relative reduction of 30% in the risk of disease progression or death, according to a study of 646 patients with relapsed or refractory multiple myeloma. Researchers found:

• Progression-free survival (PFS) rates at 1 year were 68% in the group receiving elotuzumab, lenalidomide, and dexamethasone vs 57% in the control group receiving lenalidomide and dexamethasone alone.

• At 2 years, PFS rates were 41% in the elotuzumab group vs 27% in controls.

• Median PFS in the elotuzumab group was 19.4 months vs 14.9 in controls.

• Overall response rate was 79% in the elotuzumab group vs 66% in controls.

• Common grade 3 or 4 adverse events in both groups were lymphocytopenia, neutropenia, fatigue, and pneumonia.

Citation: Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015 Aug 13;373(7):621-631. doi: 10.1056/NEJMoa1505654.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Multiple Myeloma

Caregiver burden of outpatient ASCT for multiple myeloma comparable with inpatient transplant,

Study found dual-targeted CAR T highly active against relapsed/refractory multiple myeloma,

Durable responses with anti-BCMA CAR T-cell for multiple myeloma,

Circulating miRNA could be a potential biomarker for early diagnosis of MM,